Liven Pharmaceuticals Statistics

Total Valuation

Liven Pharmaceuticals has a market cap or net worth of PKR 1.25 billion. The enterprise value is 1.24 billion.

Market Cap	1.25B
Enterprise Value	1.24B

Important Dates

The next estimated earnings date is Wednesday, February 26, 2025.

Earnings Date	Feb 26, 2025
Ex-Dividend Date	n/a

Share Statistics

Liven Pharmaceuticals has 12.12 million shares outstanding. The number of shares has increased by 166.13% in one year.

Current Share Class	n/a
Shares Outstanding	12.12M
Shares Change (YoY)	+166.13%
Shares Change (QoQ)	+664.57%
Owned by Insiders (%)	55.32%
Owned by Institutions (%)	34.22%
Float	5.07M

Valuation Ratios

The trailing PE ratio is 23.70.

PE Ratio	23.70
Forward PE	n/a
PS Ratio	13.98
PB Ratio	1.35
P/TBV Ratio	1.39
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	8.83
EV / Sales	13.91
EV / EBITDA	56.54
EV / EBIT	118.82
EV / FCF	n/a

Financial Position

The company has a current ratio of 7.26, with a Debt / Equity ratio of 0.02.

Current Ratio	7.26
Quick Ratio	4.00
Debt / Equity	0.02
Debt / EBITDA	0.89
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is 35.12% and return on invested capital (ROIC) is 1.23%.

Return on Equity (ROE)	35.12%
Return on Assets (ROA)	1.19%
Return on Capital (ROIC)	1.23%
Revenue Per Employee	29.64M
Profits Per Employee	46.65M
Employee Count	3
Asset Turnover	0.16
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +529.25% in the last 52 weeks. The beta is -0.02, so Liven Pharmaceuticals's price volatility has been lower than the market average.

Beta (5Y)	-0.02
52-Week Price Change	+529.25%
50-Day Moving Average	45.90
200-Day Moving Average	25.51
Relative Strength Index (RSI)	88.00
Average Volume (20 Days)	15,316

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Liven Pharmaceuticals had revenue of PKR 88.91 million and earned 139.96 million in profits. Earnings per share was 4.34.

Revenue	88.91M
Gross Profit	24.81M
Operating Income	10.41M
Pretax Income	124.75M
Net Income	139.96M
EBITDA	21.87M
EBIT	10.41M
Earnings Per Share (EPS)	4.34

Full Income Statement

Balance Sheet

The company has 29.33 million in cash and 19.36 million in debt, giving a net cash position of 9.97 million or 0.82 per share.

Cash & Cash Equivalents	29.33M
Total Debt	19.36M
Net Cash	9.97M
Net Cash Per Share	0.82
Equity (Book Value)	922.64M
Book Value Per Share	76.10
Working Capital	243.61M

Full Balance Sheet

Cash Flow

Operating Cash Flow	-677,925
Capital Expenditures	n/a
Free Cash Flow	n/a
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 27.91%, with operating and profit margins of 11.71% and 157.42%.

Gross Margin	27.91%
Operating Margin	11.71%
Pretax Margin	140.32%
Profit Margin	157.42%
EBITDA Margin	24.60%
EBIT Margin	11.71%
FCF Margin	n/a

Dividends & Yields

Liven Pharmaceuticals does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-166.13%
Shareholder Yield	-166.13%
Earnings Yield	4.22%
FCF Yield	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Liven Pharmaceuticals has an Altman Z-Score of 4.36.

Altman Z-Score	4.36
Piotroski F-Score	n/a